Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50744 |
Name | anaplastic large cell lymphoma |
Definition | A non-Hodgkin lymphoma involving aberrant T-cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma anaplastic large cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK fusion | Crizotinib | anaplastic large cell lymphoma | sensitive | detail... |
ALK negative | Brentuximab vedotin | anaplastic large cell lymphoma | predicted - sensitive | detail... |
ALK rearrange | N/A | anaplastic large cell lymphoma | not applicable | detail... |
ALK rearrange | Crizotinib | anaplastic large cell lymphoma | sensitive | detail... |
ALK rearrange | Ceritinib | anaplastic large cell lymphoma | sensitive | detail... |
ALK rearrange | Alectinib | anaplastic large cell lymphoma | sensitive | detail... |
ALK fusion | Crizotinib + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate | anaplastic large cell lymphoma | predicted - sensitive | detail... |
ALK rearrange | Brigatinib | anaplastic large cell lymphoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00585195 | Phase I | Crizotinib + Itraconazole Crizotinib + Rifampin | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) | Completed | USA | AUS | 2 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT00939770 | Phase Ib/II | Crizotinib | Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | USA | CAN | 0 |
NCT01196208 | Expanded access | Brentuximab vedotin | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | No longer available | USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | BGR | BEL | AUS | 2 |
NCT01449461 | Phase Ib/II | Brigatinib | A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | Completed | 0 | |
NCT01606878 | Phase I | Dexamethasone + Doxorubicin + Vincristine Sulfate Cyclophosphamide + Topotecan Crizotinib | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | USA | CAN | 0 |
NCT01686165 | Phase II | Belinostat Rituximab | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01979536 | Phase II | Crizotinib | Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | Completed | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02232516 | Phase II | Lenalidomide + Romidepsin | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02420795 | Phase Ib/II | ONC201 | Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT02464228 | Phase II | Tipifarnib | Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma | Completed | USA | ESP | 1 |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT02572453 | Phase II | Onalespib | Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
NCT02616965 | Phase I | Brentuximab vedotin + Romidepsin | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02663297 | Phase I | ATLCAR.CD30 cells | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | Active, not recruiting | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02729961 | Phase Ib/II | Brentuximab vedotin + Ceritinib | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | Withdrawn | USA | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active, not recruiting | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT03075553 | Phase II | Nivolumab | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Terminated | USA | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03372057 | Phase II | Duvelisib | A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) | Completed | USA | ITA | GBR | DEU | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03586999 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | Completed | USA | 0 |
NCT03590574 | Phase Ib/II | AUTO4 | Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma | Active, not recruiting | GBR | ESP | 0 |
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03703050 | Phase II | Nivolumab | Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL) | Recruiting | NLD | FRA | DNK | 0 |
NCT03719898 | Phase II | Brigatinib | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | Withdrawn | USA | 0 |
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Active, not recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT03905135 | Phase I | Avelumab + rhIL-15 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | Completed | USA | 0 |
NCT03947255 | Phase II | Brentuximab vedotin | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | Terminated | USA | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT04234048 | Phase I | Fenretinide | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04334174 | Phase II | Brentuximab vedotin | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T) | Withdrawn | USA | 0 |
NCT04639843 | Phase I | Azacitidine + Doxorubicin + Duvelisib + Romidepsin | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | Withdrawn | USA | 0 |
NCT04653649 | Phase Ib/II | HSP-CAR30 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | Unknown status | ESP | 0 |
NCT04703192 | Phase II | DS-3201b | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04925609 | Phase Ib/II | Brigatinib | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED) | Recruiting | NLD | FRA | 0 |
NCT04984837 | Phase II | Gemcitabine + Oxaliplatin Gemcitabine + Lacutamab + Oxaliplatin | Study of Lacutamab in Peripheral T-cell Lymphoma | Recruiting | FRA | ESP | DEU | BEL | 0 |
NCT05006664 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | Unknown status | CZE | 0 |
NCT05010005 | Phase I | Duvelisib + Ruxolitinib | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Active, not recruiting | USA | 0 |
NCT05138458 | Phase Ib/II | Cyclophosphamide + Fludarabine + MT-101 MT-101 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE) | Suspended | USA | 0 |
NCT05255601 | Phase Ib/II | Nivolumab + Relatlimab | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05274997 | Phase II | Linperlisib | A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | Unknown status | USA | 0 |
NCT05371054 | Phase Ib/II | Prednisone + Venetoclax + VIP152 | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT05883449 | Phase II | AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203) | Recruiting | USA | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT06072131 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Cyclophosphamide + Pralatrexate + Prednisone + Vincristine Sulfate Belinostat + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO) | Recruiting | USA | POL | HUN | 2 |
NCT06120504 | Phase I | SGN-35T | A Safety Study of SGN-35T in Adults With Advanced Cancers | Recruiting | USA | GBR | ESP | DNK | CAN | 0 |
NCT06176690 | Phase I | C7R.CD30.CAR-EBVS T-cells | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | Not yet recruiting | USA | 0 |
NCT06254495 | Phase I | SGN-35C | A Safety Study of SGN-35C in Adults With Advanced Cancers | Recruiting | USA | ITA | DNK | 0 |
NCT06492304 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT06508463 | Phase I | Cemiplimab + Ipilimumab + VSV-hIFNbeta-NIS | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | Recruiting | USA | 0 |
NCT06561048 | Phase III | Pralatrexate CPI-818 Belinostat | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Recruiting | USA | 0 |